Predictive biomarkers, fueling next-gen pharma pipelines.
Scailyte AG
Incorporated
19.06.2017Headquarters
BaselSupport
Scailyte pioneers single-cell biomarker discovery as this technology enters clinical trials. Our proprietary computational platform creates high-value IP and clinical assets in autoimmunity and oncology, with a model targeting Tempus AI's 10x+ ROI on data.
Our model is validated by a successful asset divestment and a pilot with a top-10 pharma now progressing to a multi-year strategic partnership. Our new IBD program leverages a cohort built on CHF 12M in public funds, plus a CHF 1M grant for our work, with LOIs currently in negotiation with two top pharma companies.
We are positioning for a Series B to scale our pharma business, targeting CHF 100M in TCV by 2027, and project a 5x-10x ROI via strategic acquisition.
News
Scailyte hits twin peaks: Extends Series A funding to USD 8 Million and transfers endometriosis diagnostic assets to Hera Biotech (venturelab.swiss)
Hera Biotech acquires endometriosis diagnostic assets from Scailyte (startupticker.ch)
Scailyte reaches USD 8 million in Series A (startupticker.ch)
Scailyte bolsters Series A funding to USD 8 Million, accelerating the innovation in the immuno-oncology landscape (venturelab.swiss)
Startups welcome seasoned industry leaders to their board (startupticker.ch)
Scailyte secures CHF 6 million to advance immuno-oncology (startupticker.ch)
Scailyte closes Series A funding with a CHF 6 million investment to develop strategic partnerships in immuno-oncology (venturelab.swiss)
"You cannot do it alone" — Interview with Christian Elias Schneider of the Innovation Office at the University of Basel (venturelab.swiss)
Plug and play Basel welcomes its first cohort (startupticker.ch)
Fourteen Swiss startups ready for scaling (startupticker.ch)
Scailyte closes Series A financing round and onboards top biotech leaders to fuel their growth in 2022 (venturelab.swiss)
Scailyte completes first close of series a round (startupticker.ch)
Scailyte ready for market growth (startupticker.ch)
A new prognostic method to fight the most dangerous cancer (startupticker.ch)
Startups attract prominent leaders to their board of directors (startupticker.ch)
Strong Swiss delegation at Bio Europe (startupticker.ch)
Scailyte announces final closing of pre-series A financing (startupticker.ch)
Scailyte CEO Peter Nestorov: 'You stop doing useful things when you do not learn and identify with a purpose' (venturelab.swiss)
10 Swiss cloud-enabled startups to watch in 2020 (venturelab.swiss)
Scailyte bags over 3 million Swiss Francs (startupticker.ch)
Milestones news
Co-development & commercialization with a UK diagnostics company
Received grant from Innosuisse for a third biomarker discovery project in partnership with Inselspital, Bern
First biomarker discovered using single-cell data and our proprietary artificial intelligence platform ScaiVision (patent pending)
Successful clinical validation of our AI technology
Received grant from Innosuisse for a second biomarker discovery project in partnership with Inselspital, Bern
Hired Director of Business Development
First customer - a S&P 100 company interested in our biomarker discovery services!
Hired Senior Data Scientist
Hired Director of Biomarker Discovery
Received grant from Innosuisse for our first biomarker discovery project in partnership with the University Hospital of Zürich
ETH Zurich spin-off recognition
Videos and Presentations
Company Presentation